Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Postdoctoral Researcher Ghada Alsaleh has been awarded a research grant by Versus Arthritis which she will use to develop a new therapy for osteoarthritis.

Ghada Alsaleh

Ghada first trained as a pharmacist before following her ambition to become a scientific researcher. She pursued her MSc and doctoral research at the University of Strasbourg working on investigating the role of a synoviocytes in rheumatoid arthritis. In 2017, she joined the University of Oxford as postdoctoral researcher.

The recently awarded Versus Arthritis Career Development Fellowship will support Ghada's proposal entitled: 'Targeting TFEB for the treatment of Osteoarthritis'. Osteoarthritis is the most common form of arthritis worldwide but lacks effective therapy. One of the main features of osteoarthritis is cartilage degradation. Preventing the loss of cartilage would halt disease progression and improve patient's quality of life.

During aging, the expression levels of a specific protein, called TFEB, dramatically fall, reducing the body's own capability for autophagy, a biological process that clears cellular debris which build up over time inside cells. This process is particularly important in old cells and often lost in older individuals. Using her fellowhip, Ghada will perform a drug screen in order to restore TFEB expression in aged individuals. This screen will allow for the identification of new drug targets for osteoarthritis and other age-related diseases.

Upon being awarded this fellowship, Ghada said: "With an increasingly aging population, age-related diseases such as osteoarthritis are becoming an increasing health burden on societies. Unfortunately, there is currently no cure or effective therapy for osteoarthritis, leaving patients often with disabling symptoms and a decreased quality of life. Most current treatments aim to manage some of these symptoms.

"In my research, I am going to explore how the expression of the protein TFEB can influence osteoarthritis pathology. I will target it in the search for new promising candidates for drug discovery approaches. The Versus Arthritis grant will help us to modulate central processes of the pathology, and not just symptoms. By doing so, we hope to stop disease progression, decrease pain and improve patients' quality of life. I feel very honoured to have been awarded this fellowship and look forward to tackling the biology and new treatment options for this disease."

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.